Medexus Pharmaceuticals Inc. (MEDXF)
| Market Cap | 59.33M |
| Revenue (ttm) | 109.54M |
| Net Income (ttm) | 3.56M |
| Shares Out | n/a |
| EPS (ttm) | 0.14 |
| PE Ratio | 16.66 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,750 |
| Average Volume | 13,028 |
| Open | 1.747 |
| Previous Close | 1.780 |
| Day's Range | 1.650 - 1.775 |
| 52-Week Range | 1.100 - 3.880 |
| Beta | 2.03 |
| RSI | 52.79 |
| Earnings Date | Apr 11, 2025 |
About Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc. operates as a pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical ... [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews
Medexus Provides Update on Progress of Commercialization of GRAFAPEX (treosulfan) for Injection
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - April 7, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to provide a business update on the progress of the commercial l...
Medexus Completes Agreement to Return US Commercialization Rights for Gleolan to NX Development Corp.
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - March 14, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed an agreement with NX Development Corp., the licensor of...
Medexus Announces Commercial Availability of GRAFAPEX (treosulfan) for Injection
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 24, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) is pleased to announce that GRAFAPEX™ (treosulfan) for Injection is now...
Medexus Pharmaceuticals, Inc. (MEDXF) Q3 2025 Earnings Call Transcript
Medexus Pharmaceuticals, Inc. (OTCQX:MEDXF) Q3 2025 Earnings Conference Call February 6, 2025 8:00 AM ET Company Participants Victoria Rutherford - IR, Adelaide Capital Ken d'Entremont - CEO Brendon B...
Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States
Fiscal Q3 2025 revenue of $30.0 million, net income of $0.7 million, operating income of $3.8 million, and Adjusted EBITDA* of $5.8 million Management to host conference call at 8:00 AM Eastern time o...
Medexus and Ontario's Provincial Health Services Successfully Complete Agreements for Public Reimbursement of Trecondyv (treosulfan for injection) in Ontario, Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 4, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed listing agreements with Ontario's Ministry of Health ...
Medexus Schedules Third Fiscal Quarter 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, Feb...
Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals Inc. (TSX: MDP) ("Medexus" or the "Company"), is pleased to announce the closing of its previously...
Medexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common Shares
The Base Shelf Prospectus is accessible, and the Prospectus Supplement will be accessible within two business days, through SEDAR+
Medexus Pharmaceuticals Announces Overnight Marketed Public Offering of Common Shares
NOT FOR DISTRIBUTION TO UNITED STATES TORONTO and CHICAGO, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (“Medexus” or the “Company”) (TSX: MDP), is pleased to announce that it has la...
Medexus Announces FDA Approval of GRAFAPEX (treosulfan) for Injection and Provides Business Update
Medexus will target a commercial launch in 1H CY2025; potential for annual product-level revenue to exceed US$100 million within five years after commercial launch Toronto, Ontario and Chicago, Illino...
Medexus and British Columbia's Provincial Health Services Authority (PHSA) Successfully Complete Agreement for Public Reimbursement of Trecondyv (treosulfan for injection) in British Columbia, Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 15, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) recently completed a listing agreement with British Columbia's Provincia...
Medexus and pan-Canadian Pharmaceutical Alliance (pCPA) Successfully Complete Negotiations for Trecondyv (treosulfan for injection) in Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - November 18, 2024) - Earlier in November 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) successfully completed a negotiation process ...
Medexus Pharmaceuticals Inc. (MEDXF) Q2 2025 Earnings Call Transcript
Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q2 2025 Earnings Conference Call November 8, 2024 8:00 AM ET Company Participants Victoria Rutherford - IR, Adelaide Capital Ken d'Entremont - CEO Brendon Bu...
Medexus Announces Strong Fiscal Q2 2025 Results
Fiscal Q2 2025 revenue of $26.3 million, net income of $0.1 million, operating income of $1.6 million, and Adjusted EBITDA* of $6.0 million Management to host conference call at 8:00 AM Eastern time o...
Medexus Schedules Second Fiscal Quarter 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - October 29, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Friday, Novem...
Medexus Holds Annual Meeting of Shareholders and Announces Election of Directors
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 19, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today held its virtual annual meeting of shareholders. Medexus shareho...
Medexus Provides Update on Treosulfan NDA Review Process and Extended PDUFA Goal Date
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - September 16, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) has been informed by medac, licensor of Medexus's commercialization ri...
Medexus Announces Strong Fiscal Q1 2025 Results
Fiscal Q1 2025 revenue of $27.3 million, net income of $2.0 million, operating income of $4.0 million, and Adjusted EBITDA* of $6.1 million Management to host conference call at 8:00 AM Eastern time o...
Medexus Schedules First Fiscal Quarter 2025 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - July 30, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Thursday, August...
Medexus Pharmaceuticals Inc. (MEDXF) Q4 2024 Earnings Call Transcript
Medexus Pharmaceuticals Inc. (OTCQX:MEDXF) Q4 2024 Earnings Conference Call June 26, 2024 8:00 AM ET Company Participants Victoria Rutherford - IR, Adelaide Capital Kenneth d'Entremont - CEO Marcel Ko...
Medexus Generates Record Revenue of US$113.1 Million in Fiscal Year 2024
FDA has Accepted for Review the Treosulfan NDA Management to host conference call at 8:00 AM Eastern time on Wednesday, June 26, 2024 Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 25,...
Medexus Schedules Fourth Fiscal Quarter and Fiscal Year 2024 Conference Call
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 18, 2024) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) plans to host a conference call at 8:00 am Eastern Time on Wednesday, June ...
FDA Accepts for Review Treosulfan NDA Resubmission
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - June 6, 2024) - On Thursday, June 6, 2024, Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus's comm...
Medexus Concludes Metoject Litigation, Patent No Longer in Effect in Canada
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - May 1, 2024) - Following a trial in January 2023, Canada's Federal Court has issued a judgment declining to uphold the Canadian patent for Met...